Drug Baron Blog
Private vs. Public: Privacy in Trials
Laura Strong (The Next Element)
Alkermes CEO Richard Pops on Building Big and Playing Well with Pharma
Ben Fidler (Xconomy)
Report Finds Huge Variations in CDER Performance, but Few Explanations as to Why
Alexander Gaffney (Regulatory Focus)
Summary from RAPS, with link to full Manhattan Institute report inside. I will have to just present this without comment unfortunately.
Drug costs and prices: Here we go again
Ashutosh Jogalekar (Scientific American)